The number of cryptocurrencies exploded as coders, entrepreneurs and scam artists jumped on the crypto-bandwagon. But as with a gold rush, fortunes can be lost as well as won.
Merryn Somerset Webb finds out more about the Smithson investment trust – who’s running it, what’s in it, and how much it will cost.
The dangers of buying a property on a long leasehold instead of a freehold are becoming clearer every day, says Merryn Somerset Webb.
Matthew Partridge talks to Nicholas Wilson of the Gulf Investment Fund about the rapidly changing face of the Gulf states, and the opportunities for investors.
It may feel like there is very little value to be found in the markets. But these three new small-cap investment trusts are betting against that, says Merryn Somerset Webb.
Soaring house prices in global capital cities have left governments scrabbling to appease angry voters who have been priced out. But are restrictions on foreign ownership the answer?
It’s been ten years since the start of the global financial crisis. John Stepek looks at how that’s affected the economy, politics and the social contract today.
MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK’s financial pages.
This year has not been kind to Japanese equities. But this looks wrong-headed given the encouraging backdrop.
With a recession looming, markets have started to worry that Argentina could have trouble meeting its financing needs. But this is a squall, not a storm.
Betting firm GVC has been boosted by the US’s removal on its sports gambling ban, while Pets at Home has seen profits dive.
The government is cracking down on overcrowded house shares. If you’re an HMO landlord, make sure you’re up to date.
South Korean stocks have a history of low dividend payouts. But things are slowly changing, says professional investor Ian Hargreaves. Here, he picks three shareholder-friendly firms to buy now.
The current turbulence of emerging markets should not come as a surprise to anyone, says Satyajit Das.
High-profile venture-capital successes tempt ordinary investors, but be careful, says Max King.
Biotech company Biogen’s promising treatment for the most common cause of dementia has just cleared a key hurdle.